Protalix BioTherapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Protalix BioTherapeutics, Inc. (PLX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $22.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-12
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $3.78M, a 2203.05% increase year-over-year.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $18.32M.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$5.50M, a 184.76% decline year-over-year.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $2.35M, a 27.22% decline year-over-year.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$6.60M, a 325.24% decline from fiscal 2024.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $2.93M, a 64.73% decline from fiscal 2023.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $8.31M.
- Protalix BioTherapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$14.93M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $22.09M 10-Q · filed 2026-08-12 | $16.59M derived: sum of 3 quarters · filed 2026-08-12 | $18.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $18.32M 10-Q · filed 2026-05-13 | $12.81M derived: sum of 2 quarters · filed 2026-05-13 | $15.17M derived: sum of 3 quarters · filed 2026-05-13 | $15.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$3.15M derived: sum of 2 quarters · filed 2026-03-18 | -$2.98M derived: sum of 3 quarters · filed 2026-08-12 | -$6.60M 10-K · filed 2026-03-18 |
| 2025-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.52M derived: sum of 2 quarters · filed 2026-08-12 | -$1.10M 10-Q · filed 2025-11-13 | $5.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$3.46M 10-Q · filed 2026-08-12 | $3.04M derived: sum of 3 quarters · filed 2026-08-12 | $6.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$3.62M 10-Q · filed 2026-05-13 | $2.88M derived: sum of 2 quarters · filed 2026-05-13 | $6.11M derived: sum of 3 quarters · filed 2026-05-13 | $3.91M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $9.73M derived: sum of 2 quarters · filed 2026-03-18 | $7.53M derived: sum of 3 quarters · filed 2026-03-18 | $2.93M 10-K · filed 2026-03-18 |
| 2024-09-30 | $3.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.03M derived: sum of 2 quarters · filed 2025-11-13 | -$3.56M 10-Q · filed 2025-11-13 | -$9.61M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-06-30 | -$2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$6.80M 10-Q · filed 2025-08-14 | -$12.84M derived: sum of 3 quarters · filed 2026-03-18 | -$14.69M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-03-31 | -$4.59M 10-Q · filed 2025-05-09 | -$10.64M derived: sum of 2 quarters · filed 2026-03-18 | -$12.49M derived: sum of 3 quarters · filed 2026-03-18 | $6.85M derived: sum of 4 quarters · filed 2026-03-18 |
| 2023-12-31 | -$6.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$7.90M derived: sum of 2 quarters · filed 2026-03-18 | $11.44M derived: sum of 3 quarters · filed 2026-03-18 | $8.31M 10-K · filed 2026-03-18 |
| 2023-09-30 | -$1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $17.49M derived: sum of 2 quarters · filed 2024-11-14 | $14.36M 10-Q · filed 2024-11-14 | $10.62M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $19.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $16.21M 10-Q · filed 2024-08-14 | $12.47M derived: sum of 3 quarters · filed 2025-03-17 | $8.90M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | -$3.13M 10-Q · filed 2024-05-10 | -$6.87M derived: sum of 2 quarters · filed 2025-03-17 | -$10.44M derived: sum of 3 quarters · filed 2025-03-17 | -$15.77M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$7.31M derived: sum of 2 quarters · filed 2025-03-17 | -$12.64M derived: sum of 3 quarters · filed 2025-03-17 | -$14.93M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$3.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$8.90M derived: sum of 2 quarters · filed 2023-11-06 | -$11.19M 10-Q · filed 2023-11-06 | -$17.85M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$7.62M 10-Q · filed 2023-08-07 | -$14.29M derived: sum of 3 quarters · filed 2024-03-14 | -$18.49M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$2.29M 10-Q · filed 2023-05-04 | -$8.95M derived: sum of 2 quarters · filed 2024-03-14 | -$13.15M derived: sum of 3 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$10.87M derived: sum of 2 quarters · filed 2024-03-14 | -$27.58M 10-K · filed 2024-03-14 | |
| 2021-09-30 | -$4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$20.91M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$16.72M 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | -$6.52M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |